scispace - formally typeset
D

Dan Zhang

Researcher at China-Japan Friendship Hospital

Publications -  9
Citations -  153

Dan Zhang is an academic researcher from China-Japan Friendship Hospital. The author has contributed to research in topics: Pharmacokinetics & Population. The author has an hindex of 2, co-authored 5 publications receiving 10 citations.

Papers
More filters
Journal ArticleDOI

Majorbio Cloud: A one‐stop, comprehensive bioinformatic platform for multiomics analyses

TL;DR: In this paper , the authors present a platform consisting of three modules, which are preconfigured bioinformatic pipelines, cloud toolsets, and online omics' courses, which combine analytic tools for metagenomics, genomes, transcriptome, proteomics and metabolomics.
Journal ArticleDOI

Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin

TL;DR: Genetic variants affect RST concentration significantly and potentially affect serum levels of pro-inflammatory and pro-angiogenic markers and the effects on anti-inflammation might not be related to high plasma exposure of RST.
Journal ArticleDOI

Imipenem Population Pharmacokinetics: Therapeutic Drug Monitoring Data Collected in Critically Ill Patients with or without Extracorporeal Membrane Oxygenation.

TL;DR: The results showed that there may be insufficient drug use in the clinical routine drug dose regimen, and 750 mg every 6 h (q6h) could achieve a higher treatment success rate.
Journal ArticleDOI

Retrospective analysis on incidence and risk factors of early onset acute kidney injury after lung transplantation and its association with mortality.

TL;DR: In this paper, the authors explore potential risk factors and outcomability of acute kidney injury (AKI) after lung transplantation, which is closely related to the poor prognosis of patients.
Journal ArticleDOI

Population Pharmacokinetics and Hemorrhagic Risk Analysis of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation

TL;DR: The population pharmacokinetic model could inform individualized dosing for elderly Chinese NVAF patients undergoing rivaroxaban anticoagulation therapy and advise for elderly patients with renal impairment to avoid overexposure and bleeding events.